World Aids Day: Gilead CEO Martin On HIV Therapy

Friday, 1 Dec 2006 | 8:44 AM ET

Today is World AIDS Day and it comes at a time when health experts are considering new strategies in an attempt to change the environment of AIDS transmission. The rate of H-I-V infection is growing--with more than four million new cases each year.

One biopharmaceutical company whose portfolio includes several HIV treatments is Gilead Sciences. The CEO of Gilead -- John Martin—spoke with Joe Kernen this morning on CNBC’s "Squawk Box."

Gilead's HIV Crusade
Today is World AIDS Day, and CNBC takes a look at Gilead, a pharma company whose portfolio includes several HIV treatments. CNBC's Joe Kernen interviews John Martin, Gilead Sciences CEO.

Martin says Gilead is one of the leading companies in HIV therapy and that Gilead has simplified AIDS therapy.

Martin goes on to say that Gilead has been at the forefront of simplifying AIDS treatments. Now-- it's a single pill taken once per day it used to be a complicated cocktail.

Patients who maintain all their medications very diligently do very well for many years--according to Martin.

Gilead is also working on therapies for Cystic Fibrosis patients who have bacterial infection of the lung. Martin revealed Gilead has products in development that can help provide better outcomes for those patients.

  Price   Change %Change


Contact Squawk Box


    Get the best of CNBC in your inbox

    › Learn More
  • Showtimes

    Weekdays 6a ET
    Weekdays 13:00 CET
    Weekdays 18:00 SIN/HK
    Weekdays 20:00 SYD
    New Zealand
    Weekdays 22:00 NZ
  • Joe Kernen is co-anchor of "Squawk Box," CNBC's signature morning program.

  • Becky Quick is co-anchor of "Squawk Box," CNBC's signature morning program. She's also a columnist for Fortune.

  • Andrew Ross Sorkin is a co-anchor of "Squawk Box," a financial columnist for "The New York Times" and the editor-at-large of NYT's DealBook.